

Manuscript Number: SPINEE-D-13-00152R2

Title: Spinal motor neurite outgrowth over glial scar inhibitors is enhanced by co-culture with bone marrow stromal cells

Article Type: Basic Science

Section/Category: Basic Science/Physiology

Keywords: Bone marrow stromal cells; Spinal motor neurites; Glial scar nerve inhibitors; Spinal cord injury

Corresponding Author: Dr. Karina Wright,

Corresponding Author's Institution: Keele University

First Author: Karina Wright

Order of Authors: Karina Wright; Kenzo Uchida; Jennifer Bara; Sally Roberts; Wagih El Masri; William Johnson

Abstract: BACKGROUND CONTEXT: Transplantation of bone marrow cells into spinal cord lesions promotes functional recovery in animal models and recent clinical trials suggest possible recovery also in humans. The mechanisms responsible for these improvements are still unclear.

PURPOSE: To characterise spinal cord motor neurite interactions with human bone marrow stromal cells (MSC) in an in vitro model of spinal cord injury (SCI).

STUDY DESIGN/SETTING: Previously we have reported that human MSC promote the growth of extending sensory neurites from dorsal root ganglia (DRG), in the presence of some of the molecules present in the glial scar which are attributed with inhibiting axonal regeneration following SCI. We have adapted and optimized this system replacing the DRG with a spinal cord culture to produce a central nervous system (CNS) model which is more relevant to the SCI situation.

METHODS: We have developed and characterised a novel spinal cord culture system. Human MSC were co-cultured with spinal motor neurites in substrate choice assays containing glial scar associated inhibitors of nerve growth. In separate experiments MSC conditioned media was analysed and added to spinal motor neurites in substrate choice assays. This study was funded by the corresponding author's institution; there are no conflicts of interest.

RESULTS: As has been reported previously with DRG, substrate-bound neurocan and Nogo-A repelled spinal neuronal adhesion and neurite outgrowth, but these inhibitory effects were abrogated in MSC/spinal cord co-cultures. However, unlike DRG, spinal neuronal bodies and neurites showed no inhibition to substrates of myelin associated glycoprotein. In addition, the MSC secretome contained numerous neurotrophic factors which stimulated spinal neurite outgrowth, but these were not sufficient stimuli to promote spinal neurite extension over inhibitory concentrations of neurocan or Nogo-A.

CONCLUSIONS: These findings provide novel insight into how MSC transplantation may promote regeneration and functional recovery in animal models of SCI and in the clinic, especially in the chronic situation where glial scars (and associated neural inhibitors) are well established. In addition, we have confirmed that this CNS model predominantly comprises of motor neurons via immunocytochemical

characterisation. We hope that this model may be used in future research to test various other potential interventions for spinal injury or disease states.

1 **Title: Spinal motor neurite outgrowth over glial scar inhibitors is enhanced**
2 **by co-culture with bone marrow stromal cells**

3 **Authors names and affiliations:** Karina T. Wright^{a,e}, Kenzo Uchida^c, Jennifer J.
4 Bara^{a,e}, Sally Roberts^{a,e}, Wagih El Masri^{b,e} and William E. B. Johnson^d.

5 ^aCentre for Spinal Studies; ^bMidlands Centre for Spinal Injuries: Robert Jones
6 and Agnes Hunt Orthopaedic Hospital, Oswestry, Shropshire, UK, SY10 7AG.

7 ^cUniversity of Fukui, Department of Orthopaedics and Rehabilitation Medicine,
8 Fukui, Japan. ^dLife and Health Sciences, Aston University, Aston Triangle,

9 Birmingham, UK, B4 7ET. ^eInstitute for Science and Technology in Medicine,
10 Keele University, Keele, Staffordshire, ST5 5BG, UK.

11 **Corresponding author:** Dr Karina T. Wright, Centre for Spinal Studies, Robert
12 Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, Shropshire, UK SY10
13 7AG. Tel: +44 (1691) 404699; Fax: +44 (1691) 404170; Email:
14 Karina.Wright@rjah.nhs.uk.

Re: SPINEE-D-13-00152R2

Title: Spinal motor neurite outgrowth over glial scar inhibitors is enhanced by co-culture with bone marrow stromal cells. Wright KT et al.

13 Dec. 13

Dear Editor,

Thank you for your consideration of the above manuscript for consideration of publication in The Spine Journal; the following points are made in response to the comments of Reviewer 3:

We are grateful to the reviewer for considering our submission further. It seems that the main (only) issue for the Reviewer is because of the evident quality of the images that have been supplied in the Figures for the paper. In particular, the Reviewer is concerned that the spinal neurons being examined may not have an appropriate morphology for spinal motor neurons. In fact, we have used SC1 immunolocalisation as a marker for motor neurons because this marker has previously demonstrated specificity for motor neurons (as documented in the script) and because morphology alone is a poor indicator of function. Furthermore, we have used isolation and culture techniques that also have been demonstrated to successfully obtain motor neurons from chick spinal cords.

Hence, whilst we understand the point that has been made, we would refute the Reviewer's concern in the first instance. However, if you think this remains an issue of note, then we would be happy to consider addressing the terminology applied to the neurons being examined, i.e., to describe them as spinal neurons rather than motor neurons, and include in the text that we have demonstrated that they are SC1 immunopositive. We hope that you agree with us that this edit is not necessary.

To solve the issue, it may be possible to improve the quality of the final figures by sending individual powerpoint files, or the tiff or jpeg files that constitute each Figure proper. Indeed, the Figures have now been submitted as Power point files to optimise resolution, which we have uploaded to the website, but because of potential difficulties of submitting in this manner, we have also sent the individual files (powerpoint files for each Figure proper) to The Spine J., along with the individual constituent tiffs for each Figure. We hope that the new files will have solved the problem of figure resolution.

Thank you for reconsidering this submission to The Spine Journal, which would be an excellent journal in which to disseminate this work. However, we would like to reiterate that it is not possible to repeat these studies.

1 **Title: Spinal motor neurite outgrowth over glial scar inhibitors is enhanced**
2 **by co-culture with bone marrow stromal cells**

3 **Abstract**

4 **BACKGROUND CONTEXT:** Transplantation of bone marrow cells into spinal
5 cord lesions promotes functional recovery in animal models and recent clinical
6 trials suggest possible recovery also in humans. The mechanisms responsible for
7 these improvements are still unclear.

8 **PURPOSE:** To characterise spinal cord motor neurite interactions with human
9 bone marrow stromal cells (MSC) in an *in vitro* model of spinal cord injury (SCI).

10 **STUDY DESIGN/SETTING:** Previously we have reported that human MSC
11 promote the growth of extending sensory neurites from dorsal root ganglia
12 (DRG), in the presence of some of the molecules present in the glial scar which
13 are attributed with inhibiting axonal regeneration following SCI. We have adapted
14 and optimized this system replacing the DRG with a spinal cord culture to
15 produce a central nervous system (CNS) model which is more relevant to the SCI
16 situation.

17 **METHODS:** We have developed and characterised a novel spinal cord culture
18 system. Human MSC were co-cultured with spinal motor neurites in substrate
19 choice assays containing glial scar associated inhibitors of nerve growth. In
20 separate experiments MSC conditioned media was analysed and added to spinal
21 motor neurites in substrate choice assays. This study was funded by the
22 corresponding author's institution; there are no conflicts of interest.

1 **RESULTS:** As has been reported previously with DRG, substrate-bound
2 neurocan and Nogo-A repelled spinal neuronal adhesion and neurite outgrowth,
3 but these inhibitory effects were abrogated in MSC/ spinal cord co-cultures.
4 However, unlike DRG, spinal neuronal bodies and neurites showed no inhibition
5 to substrates of myelin associated glycoprotein. In addition, the MSC secretome
6 contained numerous neurotrophic factors which stimulated spinal neurite
7 outgrowth, but these were not sufficient stimuli to promote spinal neurite
8 extension over inhibitory concentrations of neurocan or Nogo-A.

9 **CONCLUSIONS:** These findings provide novel insight into how MSC
10 transplantation may promote regeneration and functional recovery in animal
11 models of SCI and in the clinic, especially in the chronic situation where glial
12 scars (and associated neural inhibitors) are well established. In addition, we have
13 confirmed that this CNS model predominantly comprises of motor neurons via
14 immunocytochemical characterisation. We hope that this model may be used in
15 future research to test various other potential interventions for spinal injury or
16 disease states.

17

1 **Introduction**

2 Injury to the central nervous system (CNS) usually initiates a poor intrinsic
3 regenerative response for a number of reasons. Immune reactions, which in
4 other tissues may help to recruit reparative cells, often have a devastating effect
5 on CNS tissue function. Inflammation and ensuing secondary cascades can
6 cause extensive neuronal and glial cell death, as well as glial cell activation and
7 hypertrophy [1]. In an effort to restore the blood brain barrier, astrocytes at the
8 site of injury become reactive and synthesise a proteoglycan rich matrix [2].
9 Myelin debris associated molecules, including Nogo-A and myelin associated
10 glycoprotein (MAG), are also released from damaged neural tissues [3]. These
11 events combine to produce a hostile environment for nerve re-growth [2-6].

12 There has been extensive interest world-wide in the development of cell
13 transplantation strategies for the treatment of CNS damage, in particular spinal
14 cord injury (SCI). Many diverse potential cell therapies have been tested, each
15 targeting different distinct stages of SCI and mechanisms of spinal cord repair [7-
16 10]. Allogeneic embryonic stem cells (ES cells) and umbilical cord-derived cells,
17 as well as possible autologous cell sources, including adult neural stem cells,
18 Schwann cells and olfactory ensheathing cells have been shown to promote
19 axonal regeneration and restore function in animal models of SCI [11-17]. These
20 types of cell are thought to act in a number of ways depending on the cell type
21 transplanted, including replacing dead or damaged neurons and glia, re-
22 establishing neural networks, remyelinating demyelinated axons and reducing the
23 hostile nature of the SCI lesion.

1 Autologous cell therapies derived from bone marrow have also been
2 shown to enhance functional recovery in animal models of SCI and possibly in
3 the clinic [10], but the repair mechanisms responsible are still largely unclear.
4 Some controversial evidence exists which suggests that bone marrow cells,
5 including marrow stromal cell (MSC) and hematopoietic stem cell fractions, may
6 transdifferentiate to replace lost neurons and glia, in a manner similar to that
7 proposed for ES cells and neural stem cells [18-22]. However, the consensus of
8 opinion seems to be that for MSC transplantation at least, the most likely mode of
9 activity is an induction of a diverse myriad of paracrine anti-inflammatory
10 pathways and directly restorative cell-matrix and cell-cell interactions [23-29].

11 Previously we have used growth substrate choice assays to examine how
12 human MSC influence neurite outgrowths from explants of chick dorsal root
13 ganglia (DRG). We have demonstrated that MSC help neurites to overcome the
14 effects of some of the major nerve inhibitory molecules found in SCI lesions,
15 including neural proteoglycans, Nogo-A and MAG [30]. This established model of
16 sensory nerve growth provided an excellent platform to examine in real-time
17 possible cell-matrix and cell-cell interactions that may occur in the SCI milieu. In
18 the current study, we have adapted and refined our system by replacing DRG
19 explants with spinal cord cultures to provide a more relevant model of CNS nerve
20 growth. We envisage that the establishment of a novel spinal nerve growth
21 substrate assay, which comprises characterized motor neurons and relevant
22 neural matrix molecules, will provide an invaluable research tool for testing SCI

- 1 therapeutics, which will have further applications in the broader fields of CNS
- 2 tissue engineering and repair.
- 3

1 **Materials and methods**

2 *Ethics Statement*

3 All research involving human participants was completed with written informed
4 consent and Local Research Ethics Committee (LREC) approval: Shropshire &
5 Staffordshire Strategic Health Authority, Reference Number: 04/02/RJH. Ethical
6 approval and a Home Office project license for the study were not required under
7 the United Kingdom Animal (Scientific Procedures) Act of 1986 because chicks
8 were killed by decapitation (which is an appropriate method under Schedule 1 of
9 the Act).

10 *Human bone marrow stromal cell (MSC) culture*

11 Bone marrow aspirates or bone chips were harvested from the iliac crest of
12 individuals undergoing spinal fusion in the treatment for lumbar degenerative
13 disorders (n=5; ages 29-53). Bone marrow aspirates and bone chips were kindly
14 collected by spinal surgeons from the Centre for Spinal Disorders and sent to the
15 Spinal Studies research laboratories for processing (both based at the RJAH
16 Orthopaedic Hospital, Oswestry, UK).

17 Bone chips were perfused with Dulbecco's Modified Eagle's Medium
18 (DMEM/F12), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin
19 and streptomycin (P/S) (Invitrogen Life Technologies, Paisley, UK). Mononuclear
20 cells isolated by density gradient centrifugation at 900g for 20 minutes over
21 Lymphoprep™ (Fresenius Kabi Norge, AS) were plated out in DMEM/ 20% FBS
22 + P/S medium (Invitrogen Life Technologies) at a seeding density of 20×10^6
23 cells per flask. After 24 hours, non-adherent cells were removed and the

1 adherent cell populations were cultured in monolayer and were maintained in a
2 humidified atmosphere of 5% CO₂ at 37⁰C through to passage II-III in DMEM/
3 10% FBS + P/S medium. MSC cultures used in this study were characterised
4 according to the MSC CD immunoprofile criteria published by the International
5 Society for Cellular Therapy [31].

6 *Embryonic chick neuronal cultures*

7 Spinal cords were dissected from E4.5 hybrid brown chicks as described
8 previously [32] and cut into 10-20 pieces per cord, such that all were of
9 approximately equal size. These were then digested in 20µl of trypsin (2.5% w/v;
10 final concentration 0.05%) in PBS (Invitrogen Life Technologies) for 15 minutes
11 at 37⁰C whilst agitating frequently. The trypsin supernatant was removed and
12 replaced by 900µl of neuronal culture medium (NCM; L-15 culture medium
13 supplemented with 1% (v/v) insulin, transferrin and selenium, 1% (v/v) P/S (L-15/
14 ITS-X/ P/S medium, Invitrogen Life Technologies), 1% (v/v) horse serum and
15 1.5mg/ml glucose) (Sigma-Aldrich, Poole, UK) and 100µl of 4% (w/v) bovine
16 serum albumin (BSA; Sigma-Aldrich). The spinal cord tissue was homogenized
17 using a pipette and spinal cord motor neurons were isolated by density gradient
18 centrifugation at 500g for 15 minutes over a warmed 1.5ml cushion of 6.8% (v/v)
19 Nycodenz® (Serva, Heidleberg, Germany). Dissociated cells were seeded into
20 24-well tissue culture plates (Co-star, Corning Inc, NY) pre-coated with nerve-
21 permissive and nerve-inhibitory molecules (see below) in NCM supplemented
22 with 0.4% (v/v) N2-supplement and 10ng/ml basic fibroblast growth factor (bFGF)

1 (Invitrogen Life Technologies) at a seeding density of 3×10^5 cells per well and
2 were maintained in a humidified atmosphere of 5% CO₂ at 37⁰C for 72 hours.

3 *Optimisation of chick neuronal culture growth substrata*

4 Briefly, some wells were pre-coated with a thin layer of protein-binding
5 nitrocellulose (BA85, Schleicher & Schuell, Dassel, Germany). Pre-coated and
6 uncoated plates were then further incubated with either PBS or 25µg/ml laminin
7 (derived from Engelbreth-Holm-Swarm mouse tumour, BD Biosciences, Oxford,
8 UK) in PBS. After coating, all wells were washed repeatedly with PBS prior to
9 seeding with neuronal cultures. Control DRG plates for SC1 immunostaining
10 were established using embryonic chick day 10 DRG as described previously
11 [30].

12 *MSC/ neuronal co-cultures*

13 MSC were labelled with Cell Tracker™ Red Fluorescent Probe (Cambrex
14 Bioscience, Wokingham, UK) following the manufacturer's protocol. Labelled
15 cells were seeded (at a density of 5×10^3 cells/ cm²) in DMEM/ 10% FBS + P/S
16 into plates coated with nerve-permissive and nerve-inhibitory substrata (see
17 below). After 24 hours, any non-adherent cells were removed and wells washed
18 repeatedly before adding N2 and bFGF-supplemented NCM. Neuronal cultures
19 were then immediately seeded into each well and the MSC/ neuronal co-cultures
20 maintained in a humidified atmosphere of 5% CO₂ at 37⁰C for 72 hours. Control
21 plates of neuronal cultures seeded alone, i.e., without pre-seeded MSC, were
22 established at the same time in N2 and bFGF-supplemented NCM.

23 *Mixed substrate preparation*

1 Neurocan, isolated from embryonic chick brains and purified with a monoclonal
2 antibody (Millipore, Billerica, MA), was used to coat tissue culture plates in
3 restricted localities, as described previously [30, 33,34]. Briefly, wells were pre-
4 coated with a thin layer of protein-binding nitrocellulose (see above), which was
5 then blotted with 350µm wide strips of filter paper (Whatman No.1, GE
6 Healthcare, Maidstone, Kent, UK) that had been soaked in neurocan at
7 concentrations ranging from 1µg-50µg/ml (in PBS). After the filter strips had dried
8 and been removed, the plates were then washed with PBS. The restricted
9 localisation of the neurocan on the culture plates was visualized by inclusion of a
10 marker dye (5% v/v rhodamine B, Sigma-Aldrich) in the neurocan solution. The
11 same technique was used to prepare culture plates with substrates of 10-
12 400µg/ml recombinant Nogo-A on nitrocellulose or 10-400µg/ml recombinant
13 MAG on nitrocellulose (both R&D Systems, Abbingdon, UK). After coating, all
14 wells were washed repeatedly with PBS prior to seeding with neuronal cultures
15 and/ or MSC.

16 *SC1 and neurofilament (NF) 200kD immunostaining*

17 SC1 is a cell surface adhesion molecule expressed on motor neuron cell bodies
18 and axons [35], which can be used to purify motor neurons from spinal cord
19 tissues [36]. Neuronal cell cultures were immunolabelled with SC1 for motor
20 neuron characterisation, whereas NF immunolabelling was used for neurite
21 quantitation because the NF immunofluorescence was much stronger and hence
22 better for the counting of fine neurite extensions.

1 Neuronal cell cultures were fixed by gently adding an equal volume of 4%
2 (w/v) buffered paraformaldehyde (BDH Biosciences) to the culture medium in
3 each well for 10 minutes. Wells were washed with PBS twice for 10 minutes.
4 Cells were then incubated for 1 hour with a blocking buffer of 10% goat serum
5 (Vector Laboratories, Burlingame, CA) in PBS at room temperature. Mouse
6 monoclonal anti-SC1 (neat) (kindly donated by Prof Hideaki Tanaka, Kumamoto
7 University, Japan) or anti-NF (1:200) (clone NE14, Sigma-Aldrich) were used as
8 the primary antibodies, and goat anti-mouse Alexa Fluor 488 (1:100) (Invitrogen
9 Life Technologies) was used as a secondary antibody. Cells were incubated with
10 the primary antibody for 1 hour and the secondary antibody for 40 minutes at
11 room temperature to stain neuronal bodies and their neurites fluorescent green.

12 *Fibronectin and laminin immunostaining*

13 MSC cultures were fixed by gently adding an equal volume of 4% (w/v) buffered
14 paraformaldehyde to the culture medium in each well for 10 minutes. Wells were
15 washed with PBS twice for 10 minutes. Cells were then incubated for 20 minutes
16 with a blocking buffer of 15% horse serum (Vector Laboratories) in PBS at room
17 temperature. Rabbit polyclonal anti-fibronectin (250 μ g/ml) or anti-laminin
18 (25 μ g/ml) (both, Sigma-Aldrich) were used as the primary antibodies, and
19 biotinylated goat anti-rabbit (50 μ g/ml, Vector Labs) was used as a secondary
20 antibody followed by a fluorescein-streptavidin complex (20 μ g/ml, Vector Labs).

21 **Parallel wells were incubated in the same blocking buffer as negative controls for**
22 **polyclonal antibodies. Cells were incubated with the primary antibody or blocking**

1 buffer overnight, the secondary antibody for 40 minutes and the fluorescein-
2 streptavidin complex for 20 minutes at room temperature.

3 *MSC-CM neuronal culture assays*

4 MSC-CM (n=6) were generated as described previously [30] and stored at -20°C
5 prior to use. In brief, MSC cultures at 70% confluence were incubated in serum
6 free DMEM supplemented with antibiotics at 37°C, 5% (v/v) CO₂ for 48 hours.

7 The MSC-CM generated from these cultures was passed through a 0.2µm filter
8 (Becton Dickinson Biosciences) to remove any cell debris and stored at -20°C
9 prior to use, which was within one week of collection. Neuronal cell cultures were
10 seeded in MSC-CM in culture plates that had either been uniformly coated in
11 nitrocellulose or coated with nitrocellulose and strips of neurocan (50µg/ml) or
12 Nogo-A (400µg/ml), as described above. Control neuronal cultures were
13 maintained in non-conditioned media under the same conditions. Neurite
14 outgrowth was measured after 72 hours in culture.

15 *MSC-CM neurotrophic protein arrays*

16 MSC-CM were screened for a panel of 23 neurotrophic proteins using custom
17 designed antibody arrays (RayBiotech Inc, Norcross, GA) according to the
18 manufacturer's instructions. In brief, array membranes with protein antibodies
19 spotted in duplicate were incubated with blocking buffer for 30 minutes at room
20 temperature. MSC-CM were thawed and incubated with the membranes
21 overnight at 4°C. Membranes were washed and then incubated with a Biotin-
22 conjugated antibody for 1 hour. Wash steps were repeated as before and
23 membranes incubated with HRP-conjugated streptavidin for 2 hours. Following

1 another series of wash steps, membranes were incubated with a
2 chemiluminescent detection reagent provided in the kit for 2 minutes. Positive
3 signals were visualised with a chemiluminescence imaging system (ChemiDoc™
4 EQ, Bio-Rad Laboratories Srl, Italy). Array data was semi-quantified by
5 measuring the sum of the intensities of the pixels within each spot boundary x
6 pixel area, with image analysis software (Quantity One® version 4.6.3, Bio-Rad,
7 Italy). A signal from a clear part of the array was subtracted from all data to
8 account for background signal. A mean was taken from the two duplicate spots
9 for each factor. Levels of neurotrophic factors were normalised to positive
10 controls (provided in the kit) and to the number of MSC that had generated a
11 standard volume of conditioned media.

12 *Microscopy, image capture and analysis*

13 Cultures were viewed using phase contrast and fluorescence microscopy (Nikon
14 Eclipse TS100, Nikon, Kingston-upon-Thames, UK). Digitized images were
15 captured with a black and white Hamamatsu digital camera (C4742-95) and
16 examined using IPLab software (Version 3.6, Nikon). For determination of the
17 optimal substrate for growth of embryonic chick spinal neuronal cultures, cell
18 aggregates and neuronal adhesion, and neurite outgrowth were counted using
19 phase contrast and fluorescence images. A cell aggregate was determined as a
20 cluster of more than one adhered cell visible under phase microscopy. NF
21 immunolabelling, visible under fluorescence microscopy was used to stain
22 neurites and to determine those cell aggregates that were of a neuronal
23 phenotype. Hence, those cell aggregates that were immunopositive for NF and

1 possessed neurites (that is, if a neurite $\geq 25\mu\text{m}$ in length were in contact with a
2 neuronal cell aggregate) were then described as 'neuronal bodies'. For substrate
3 choice assays, the number of neuronal bodies with neurites that had adhered
4 onto substrates of plastic, nitrocellulose, laminin, neurocan, Nogo-A or MAG were
5 quantified using fluorescent images. For all analysis, adhered neuronal bodies
6 with neurites were counted after 72 hours in culture. The number of red
7 fluorescent MSC that were present on the nitrocellulose, neurocan, Nogo-A or
8 MAG substrates in each digitized image was also scored. For substrate choice
9 assay quantitation, results from at least 5 separate cultures and 5 separate
10 images per culture were pooled and combined and examined using IPLab
11 software (Version 3.6, Nikon).

12 MSC-CM neurite outgrowth assays were viewed and quantified using
13 phase contrast microscopy and digitized images captured and examined using
14 the Cell IQ® Imagen system and Analyser software (Chip-Man Technologies,
15 Tampere, Finland). In brief, phase contrast images of cultures (n=12 controls and
16 n=24 MSC-CM) were captured using a fully automated system every 2-3h over a
17 period of 72 hours. From these images, the Cell-IQ® Analyser software
18 automated search tool 'neurite finder' generated temporal neurite length data for
19 each culture condition.

20 *Statistical analysis*

21 The Mann-Whitney *U* test was used to assess significant differences: (i) between
22 the frequency of neuronal bodies adhered with extending neurites onto uniform
23 substrates of plastic, nitrocellulose and laminin, (ii) between the frequency of

1 neuronal bodies adhered with extending neurites onto each of the adjacent
2 substrates in substrate choice assays of nitrocellulose versus neurocan, Nogo-A
3 or MAG in neuronal and MSC co-cultures, compared to control neuronal cultures
4 alone, (iii) between the frequency of MSC adhered onto each of the adjacent
5 substrates in substrate choice assays of nitrocellulose versus neurocan, Nogo-A
6 or MAG. The relationship between the relative amounts of each neurotrophic
7 protein and the total neurite outgrowth in each MSC-CM was determined using
8 the Spearman ranked correlation coefficient *rs*.

9 **Results**

10 *Nitrocellulose substrates promote optimal growth of embryonic chick spinal*
11 *neuronal cultures.*

12 Embryonic chick spinal cells formed aggregates which adhered to both plastic
13 and nitrocellulose substrates with or without laminin coating to varying degrees
14 (Fig 1A). A number of fibroblastic cells adhered to substrates of plastic alone; a
15 small proportion of these cells extended neurites but these were difficult to
16 distinguish from neighbouring aggregates in close proximity. Cells seeded onto
17 substrates of plastic coated with laminin or nitrocellulose formed discrete cell
18 aggregates and the majority of these aggregates possessed neurites. The
19 frequency of neurites was increased on substrates of plastic coated with
20 nitrocellulose compared to plastic (with or without laminin) (Fig 1B). For
21 substrates of nitrocellulose coated plastic with laminin, fibroblastic cells were so
22 confluent they could not be reliably separated for quantitation.

1 Embryonic chick spinal cell aggregates and neurites were then fixed and
2 immunostained for neurofilament (NF) (Fig 1C). A large proportion of those cell
3 aggregates which had adhered to plastic alone were lost following fixation and
4 immunostaining. The discrete cell aggregates which had adhered to the laminin
5 or nitrocellulose coated plastic were identified as NF immunoreactive. Those NF
6 immunoreactive cell aggregates that had extended NF immunoreactive neurites
7 were identified as neuronal bodies. The frequency of neuronal bodies was
8 increased on substrates of nitrocellulose coated plastic compared to plastic (with
9 or without laminin) (Fig 1D). For substrates of nitrocellulose coated plastic with
10 laminin, there was no clear aggregation of NF immunoreactive cells to form
11 discrete neuronal bodies, with a confluence of cells growing across the substrate
12 instead; hence the distribution of discrete NF immunoreactive neuronal bodies
13 with neurites could not be measured.

14 *Embryonic chick spinal neuronal cultures are immunopositive for the motor*
15 *neuron marker SC1*

16 Embryonic chick dorsal root ganglion (DRG) cultures were negative for SC1
17 immunocytochemical staining as were isotype matched control wells (Figs 2A
18 and 2B). In contrast, a large proportion (over 99%, data not included) of spinal
19 neuronal cultures were immunopositive for SC1 (with corresponding negative
20 staining of isotype matched control wells) (Figs 2C-D). Uniform SC1 staining of
21 spinal neuronal cultures was visible over large regions of interest, demonstrating
22 that almost all spinal neurites visible under phase microscopy were SC1
23 immunopositive (Fig 2E). Under high magnification the numerous cell bodies

1 which contribute to the formation of neuronal bodies were clearly visible. SC1
2 staining appeared to uniform throughout the main neuronal cell cluster and along
3 each individual neurite (2F).

4 *Embryonic chick spinal neuronal cultures are inhibited by neurocan and Nogo-A*
5 *but not MAG*

6 Neuronal bodies with neurites were repelled by neurocan and Nogo-A in a
7 concentration-dependent manner (Fig 3A and 3B). At high neurocan and Nogo-A
8 concentrations (50µg/ml and 400µg/ml respectively), neuronal adhesion and
9 neurite outgrowth was almost completely inhibited (<1 neuronal cell aggregate
10 with at least one neurite per image). At lower neurocan and Nogo-A
11 concentrations (1-10µg/ml and 10-200µg/ml respectively), increasing numbers of
12 neuronal bodies and neurites adhered to neurocan and Nogo-A substrates and
13 extended neurites. In contrast, neuronal cultures seeded onto nitrocellulose:
14 MAG substrate assays showed no preference for either substrate, i.e. neuronal
15 bodies and neurites were not inhibited by MAG at any concentration (5-400µg/ml)
16 (Fig 3C). No evidence of neuronal cell death (as delineated by cell detachment or
17 ethidium bromide nuclear localisation, data not included) was observed in any of
18 the cultures tested.

19 *MSC promote embryonic chick spinal neuronal adhesion and neurite extension*
20 *over substrata of neurocan, Nogo-A and MAG*

21 In MSC/ neuronal co-cultures, neuronal bodies were able to adhere and extend
22 neurites over high neurocan and Nogo-A concentrations, such that ~5 neuronal
23 bodies with neurites per image were present on 50µg/ml neurocan and ~3

1 neuronal bodies with neurites per image were present on 400 μ g/ml Nogo-A.
2 However, the inhibitory effects of neurocan and Nogo-A on neuronal adhesion
3 and neurite outgrowth were only partially abrogated when compared to
4 substrates of nitrocellulose. Some of the pre-seeded MSC appeared to align at
5 the borders of nitrocellulose with neurocan or Nogo-A, suggesting that these cells
6 were also inhibited by the nerve-inhibitory matrix molecules. However, it was
7 apparent that even at high neurocan and Nogo-A concentrations, some MSC
8 were still able to adhere to the neurocan and Nogo-A substrates and it was to
9 these MSC that the adherent neuronal bodies and neurites were often co-
10 localised (Figs 4A and 4B). MSC, neuronal bodies and neurites were not inhibited
11 by MAG at any concentration (5-400 μ g/ml) (Fig 4C). Nonetheless, neuronal
12 adhesion and neurite extension was increased on all substrates, including
13 neurocan, Nogo-A, MAG and nitrocellulose when in co-culture with MSC in
14 comparison to the absence of MSC. In addition, MSC traversing inhibitory
15 substrata were immunopositive for the nerve permissive matrix molecules laminin
16 and fibronectin (Fig 4D).

17 *MSC conditioned media (MSC-CM) promotes spinal neurite outgrowth over*
18 *nitrocellulose but not neurocan or Nogo-A inhibitory substrata*

19 MSC-CM significantly increased spinal neurite extension over nitrocellulose
20 substrates compared to control cultures in non-conditioned media (Fig 5A). We
21 have detected several neurotrophic proteins in MSC-CM which may be important
22 in stimulating spinal neurite outgrowth (Fig 5B). Of the neurotrophic factors
23 identified, the levels of granulocyte colony stimulating factor (GCSF), fibroblast

1 growth factor-4 (FGF-4) and matrix metalloproteinase-8 (MMP-8) correlated
2 significantly to the quantity of neurite outgrowth detected (Spearman Rank *rs*
3 0.57, $p=^*0.014$, *rs* 0.57, $p=^{***}<0.0001$ and *rs* 0.66, $p=^{**}0.0032$ respectively).
4 However, MSC-CM alone was not sufficient stimulus to promote neurite
5 outgrowth over inhibitory concentrations of neurocan or Nogo-A (Fig 5C).

1 **Discussion**

2 MSC transplantation for the treatment of SCI has proven efficacious in terms of
3 promoting axonal regeneration and functional recovery in animal models and
4 possibly in the clinic [10]. However, few definitive experiments have addressed
5 the mechanisms involved in this process. We have developed a substrate choice
6 assay to examine how spinal nerves interact in co-culture with MSC, specifically
7 in the context of molecules that are present at the site of SCI and that are
8 considered to form major inhibitors to axonal regeneration. Using this model we
9 have shown that spinal neuronal bodies and neurites are inhibited by neurocan
10 and Nogo-A in a concentration dependent manner, akin to DRG sensory
11 neurites, which we have reported previously [30]. Increased concentrations of
12 these extracellular inhibitors, however, were required to observe a similarly
13 'complete' inhibition, e.g. 50 μ g/ml of neurocan and 400 μ g/ml Nogo-A completely
14 inhibited spinal neurites, compared to 10 μ g/ml of neural proteoglycans (which
15 includes neurocan) and 200 μ g/ml Nogo-A for the complete inhibition of DRG
16 neurite outgrowth. However, unlike DRG sensory neurites, spinal cultures were
17 not inhibited by MAG substrates at any of the concentrations tested (up to
18 400 μ g/ml). Hence, using this CNS system we have shown that one of the
19 proposed inhibitors in the glial scar (MAG) may not be as potent in CNS systems
20 as it is in DRG systems, which may have important implications for our
21 understanding of nerve growth inhibition in the SCI setting. There is some
22 supportive evidence in the literature for these findings which suggest that MAG
23 may not be a crucial inhibitor of axonal regeneration in the CNS. For example,

1 Bartsch et al. [37] have shown that MAG deficient mice exhibit poor axonal
2 regrowth following either optic nerve or corticospinal tract transection *in vivo*,
3 although MAG has been shown by others to repel both peripheral nervous
4 system (PNS) and CNS nerve growth [30, 38, 39].

5 There are a number of distinctions between these neuronal cultures which
6 might account for the differences we have observed in their response to
7 substrate choice assays, compared to those results previously reported. The
8 most obvious is the developmental stage of each tissue source; in the current
9 study, spinal cultures were isolated 4.5 days after fertilization, compared to our
10 previous work using DRG explants from day 10 embryos [30]. The expression of
11 axonal guidance ligands and receptors, including myelin receptors are known to
12 change throughout CNS and PNS development [40-44], which may explain why
13 spinal and DRG cultures exhibit different sensitivities to MAG. In addition, both
14 our current and previous methods of primary neuronal culture isolation included
15 few (if any) purification steps and hence, these cultures are composed of mixed
16 cell populations. We are in the process of characterising those ‘fibroblast-like’
17 cells visible in CNS and PNS cultures, which are likely to have influenced the
18 sensitivity of neuronal cultures in substrate ‘choice’ assays. There is a possibility
19 that other CNS cell types may have reduced the sensitivity of spinal neurites to
20 MAG substrates, perhaps by physically masking or blocking inhibitory epitopes,
21 or by secreting growth factors that blocked the inhibitory effects of MAG, e.g.
22 brain derived neurotrophic factor (BDNF) [45]. In contrast, Schwann cells, which
23 may be present in mixed PNS cultures, could exacerbate sensory nerve reactivity

1 to MAG via an additive effect, as Schwann cells themselves express nerve
2 inhibitory MAG [46]. Furthermore, each culture environment varies greatly in
3 media composition and growth factor supplementation which may also impact
4 directly on the sensitivity of neurites to inhibitory substrates, including MAG [45,
5 47]. For example, the exposure to neurotrophins has been shown to upregulate
6 chimaerin (one of the Rho-GTPase activating proteins) in cerebellar neurons [48].
7 The expression of chimaerin in the cerebellum is correlated with abolishment of
8 the inhibitory effects of MAG in development and ectopic expression of chimaerin
9 in cerebellar neurons *in vitro* results in resistance to MAG induced neurite
10 inhibition [48].

11 We have demonstrated that MSC co-culture reduces the inhibitory effects
12 of neurocan and Nogo-A on spinal neuronal adhesion and neurite outgrowth and
13 enhances spinal neurite outgrowth over all of the substrates tested (neurocan,
14 Nogo-A, MAG and nitrocellulose). We have also shown that MSC were repelled
15 by high concentrations of neurocan and Nogo-A (but not MAG substrates).
16 Hence, at high concentrations MSC could clearly be seen to align along inhibitory
17 neurocan and Nogo-A borders. Although MSC were inhibited to a much lesser
18 extent than spinal neuronal bodies and their associated neurites. This is not too
19 surprising as we already know that MSC may have an increased capacity to
20 adhere to and migrate over neural proteoglycans, Nogo-A and MAG compared to
21 other cell types [30]. The exact mechanisms responsible for the abrogation of
22 spinal nerve inhibition to neurocan and Nogo-A in MSC co-cultures may involve a
23 number of complex paracrine, cell-matrix and cell contact-mediated interactions.

1 We and others have previously reported that MSC-CM promotes neurite
2 outgrowth from DRG explants and that and that MSC synthesise a number of
3 soluble cytokines and other growth factors that are known to stimulate nerve
4 extension including NGF, BDNF and vascular endothelial growth factor [26, 30,
5 49]. In this study we have shown that MSC-CM promotes spinal neurite
6 outgrowth and contains several neurotrophic proteins, including GCSF, FGF-4
7 and MMP-8 which significantly correlated to the level of spinal neurite stimulation
8 observed. However, we show that MSC-CM alone was insufficient stimuli to
9 promote spinal neurite extension over inhibitory concentrations of neurocan or
10 Nogo-A.

11 There are other explanations which might account for spinal neurites
12 extending over inhibitory substrates in MSC co-cultures. MSC are known to
13 synthesise numerous extracellular matrices that support neuronal cells and
14 provide an optimal surface for nerve growth [50]. We have shown using our
15 model that migrating MSC provide permissive matrix 'bridges' of laminin and
16 fibronectin over nerve inhibitory substrates. In addition, in many sequences and
17 on all inhibitory substrata tested, MSC and spinal neurites co-localised. Whereby
18 MSC appeared to act as adhesive 'stepping stones' for neurite extension.
19 Alternatively, nerve-inhibitory molecules, particularly neural proteoglycans such
20 as neurocan, may have been degraded by matrix metalloproteinases (MMPs),
21 e.g. MMP-1, MMP-2, MMP-13, which MSC are known to synthesise [51]. We
22 have previously demonstrated that cell contact-mediated events, such as towing
23 of neurites and bridging of inhibitory substrata, may play an important role in

1 MSC abrogating the DRG nerve-inhibitory effects of neural proteoglycans, Nogo-
2 A and MAG [30]. Further experimentation using this system will aim to elucidate
3 which of these mechanisms contribute to MSC stimulation of spinal neurite
4 outgrowth over neurocan and Nogo-A, and to what extent. This may help to
5 identify molecular targets to further enhance nerve growth in SCI environments.

6 There are few primary motor neuron culture protocols available for
7 scientists to examine new therapies for CNS repair, particularly in the context of
8 the injured spinal cord. We have modified an existing protocol [32] to test
9 embryonic motor neurons, as characterised by SC1 staining, cultured on
10 substrate choice assays. However, we acknowledge that our characterisation of
11 spinal motor neuron cultures could be improved, e.g. by demonstrating a time
12 course of viability and functionality (at least in theory), which we aim to
13 investigate in future studies. None the less, we suggest that the development of
14 this assay and its refinement for the testing of adult spinal motor neurite
15 outgrowth over different growth surfaces will provide a valuable tool to examine
16 motor neuron and glial cell-matrix and cell-cell interactions, not readily achieved
17 when using complex *in vivo* models. We anticipate that this novel system may
18 help to further elucidate some of the mechanisms of increased axonal
19 regeneration that has been noted following MSC transplantation for the treatment
20 of SCI, as well as having wider application in the field of spinal therapeutics.

21

1 **References**

- 2 1. Ramer MS, Harper GP, Bradbury EJ. Progress in spinal cord research.
3 Spinal Cord 2000;38;449-72.
- 4 2. Fawcett JW, Asher RA. The glial scar and central nervous system repair.
5 Brain Res Bull 1999;49;377-91.
- 6 3. Tang S, Qiu J, Nikulina E, Filbin MT. Soluble Myelin-Associated
7 Glycoprotein Released from Damaged White Matter Inhibits Axonal
8 Regeneration. Mol Cell Neurosci 2001;18;259-69.
- 9 4. McKerracher L, David S, Jackson DL, Kottis V, Dunn RJ, Braun PE.
10 Identification of myelin-associated glycoprotein as a major myelin-derived
11 inhibitor of neurite outgrowth. Neuron 1994;13;805-811.
- 12 5. DeBellard M-E, Tang S, Mukhopadhyay G, Shen Y-J, Filbin M. Myelin-
13 Associated Glycoprotein Inhibits Axonal Regeneration from a Variety of
14 Neurons via Interaction with a Sialoglycoprotein. Mol Cell Neurosci
15 1996;7;89-101.
- 16 6. Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA,
17 Christ F, Schwab ME. Nogo-A is a Myelin-Associated Neurite Outgrowth
18 Inhibitor and an Antigen for Monoclonal Antibody IN-1. Nature
19 2000;403;433-45.
- 20 7. Ronaghi M, Erceg S, Moreno-Manzano V, Stojkovic M. Challenges of
21 stem cell therapy for spinal cord injury: human embryonic stem cells,
22 endogenous neural stem cells, or induced pluripotent stem cells? Stem
23 Cells 2010;28;93-9.
- 24 8. Sahni V, Kessler JA. Stem cell therapies for spinal cord injury. Nat Rev
25 Neurol 2010;6;363-72.
- 26 9. Park DH, Lee JH, Borlongan CV, Sanberg PR, Chung YG, Cho TH.
27 Transplantation of umbilical cord blood stem cells for treating spinal cord
28 injury. Stem Cell Rev 2011;7;181-194.
- 29 10. Wright KT, El Masri W, Osman A, Chowdhury J, Johnson WEB. Bone
30 Marrow for the Treatment of Spinal Cord Injury: Mechanisms and Clinical
31 Applications. Stem Cells 2011;29;169-78.
- 32 11. Guest JD, Rao A, Olson L, Bunge MB, Bunge RP. The Ability of Human
33 Schwann Cell Grafts to Promote Regeneration in the Transected Nude rat
34 Spinal Cord. Exp Neurol 1997;148;502-22.
- 35 12. Li Y, Field PM, Raisman G. Repair of adult rat corticospinal tract by
36 transplants of olfactory ensheathing cells. Science 1997;277;2000-2.

- 1 13. Ramon-Cueto A, Plant, GW, Avila J, Bunge MB. Long-Distance Axonal
2 Regeneration in the Transected Adult Rat Spinal Cord is Promoted by
3 Olfactory Ensheathing Glia Transplants. *J Neurosci* 1998;18;3803-15.
- 4 14. McDonald JW, Liu X-Z, Qu Y, Liu S, Mickey SK, Turetsky D, Gottlieb DI,
5 Choi DW. Transplanted embryonic stem cells survive, differentiate and
6 promote recovery in injured rat spinal cord. *Nat Med* 1999;5;1410-12.
- 7 15. Teng YD, Lavik EB, Qu X, Park KI, Ourednik J, Zurakowski D, Langer R,
8 Snyder EY. Functional recovery following traumatic spinal cord injury
9 mediated by a unique polymer scaffold seeded with neural stem cells.
10 *Proc Natl Acad Sci* 2001;99;3024-29.
- 11 16. Pfeifer K, Vroeman M, Blesch A, Weidner N. Adult neural progenitor cells
12 provide a permissive guiding substrate for corticospinal axon growth
13 following spinal cord injury. *Eur J Neurosci* 2004;20;1695-1704.
- 14 17. Yang C-C, Shih Y-H, Ko M-H, Cheng H, Fu Y-S. Transplantation of
15 Human Umbilical Mesenchymal Stem Cells from Wharton's Jelly after
16 Complete Transection of the Rat Spinal Cord. *PLoS ONE* 2008;3;e3336.
- 17 18. Krabbe C, Zimmer J, Meyer M. Neural transdifferentiation of mesenchymal
18 stem cells – a critical review. *APMIS* 2005;113;831-44.
- 19 19. Phinney DG, Isakova, I. Plasticity and therapeutic potential of
20 mesenchymal stem cells in the nervous system. *Curr Pharm Des*
21 2005;11;1255-65.
- 22 20. Sigurjonsson OE, Perreault M-C, Egeland T, Glover JC. Adult human
23 hematopoietic stem cells produce neurons efficiently in the regenerating
24 chicken embryo spinal cord. *Proc Nat Acad Sci* 2005;102;5227-32.
- 25 21. Chen Y, Teng FY, Tang BL. Coaxing bone marrow stromal mesenchymal
26 stem cells towards neuronal differentiation: Progress and uncertainties.
27 *Cell Mol Life Sci* 2006;63;1649-57.
- 28 22. Brazilay R, Melamed E, Offen D. Introducing transcription factors to
29 multipotent mesenchymal stem cells: Making transdifferentiation possible.
30 *Stem Cells* 2009;27;2509-15.
- 31 23. Chopp M, Zhang XH, Li Y, Wang L, Chen J, Lu D, Lu M, Rosenblum M.
32 Spinal cord injury in rat: treatment with bone marrow stromal cell
33 transplantation. *Neuroreport* 2000;11;3001-5
- 34 24. Hofstetter CP, Schwarz EJ, Hess D, Widenfalk J, El Manria A, Prockop
35 DJ, Olson L. Marrow stromal cells form guiding strands in the injured
36 spinal cord and promote recovery. *Proc Natl Acad Sci* 2002;99;2199-204.

- 1 25. Ankeny D, McTigue DM, Jakeman, LB. Bone marrow transplants provide
2 tissue protection and directional guidance for axons after contusive spinal
3 cord injury in rats. *Exp Neurol* 2004;190;17-31.
- 4 26. Neuhuber B, Himes BT, Shumsky JS, Gallo G, Fischer I. Axon growth and
5 recovery of function supported by human bone marrow stromal cells in the
6 injured spinal cord exhibit donor variations. *Brain Res* 2005;1035;73-85.
- 7 27. Himes BT, Neuhuber B, Coleman C, Kushner R, Swanger SA, Kopen GC,
8 Wagner J, Shumsky JS, Fischer I. Recovery of function following grafting
9 of human bone marrow-derived stromal cells into the injured spinal cord.
10 *Neurorehabil Neural Repair* 2006;2;278-96.
- 11 28. Birdsall Abrams MB, Dominguez C, Pernold K, Reger R, Wiesenfeld-Hallin
12 Z, Olson L, Prockop D. Multipotent mesenchymal stromal cells attenuate
13 chronic inflammation and injury-induced sensitivity to mechanical stimuli in
14 experimental spinal cord injury. *Restor Neurol Neurosci* 2006;27;301-21.
- 15 29. Nakajima H, Uchida K, Rodriguez Guerrero A., Watanabe S, Sugita D,
16 Takeura N, Yoshida A, Long G, Wright K, Johnson E, Baba H.
17 Transplantation of Mesenchymal Stem Cells Promotes the Alternative
18 Pathway of Macrophage Activation and Functional Recovery after Spinal
19 Cord Injury. *J Neurotrauma* 2012;29;1614-25.
- 20 30. Wright KT, El Masri, W, Osman A, Roberts S, Chamberlain G, Ashton BA,
21 Johnson WEB. Bone marrow stromal cells stimulate neurite outgrowth
22 over neural proteoglycans (CSPG), myelin associated glycoprotein and
23 Nogo-A. *Biochem Biophys Res Comm* 2007;354;559-66.
- 24 31. Dominici M, Blanc KL, Mueller I, Slaper-Cortenbach I, Marini FC, Krause
25 DS, Deans RJ, Keating A, Prockop DJ, Horwitz EM. Minimal criteria for
26 defining multipotent mesenchymal stromal cells. The International Society
27 for Cellular Therapy position statement. *Cytotherapy* 2006;8;315-17.
- 28 32. Henderson CE, Bloch-Gallego E, Camu W. Purified embryonic
29 motoneurons. In: Cohen JC, Wilkin GP eds. *Neural cell culture: a practical
30 approach*. IRL Press at Oxford University Press, 1995:69-81.
- 31 33. Snow DM, Lemmon V, Carrino DA, Caplan AI, Silver J. Sulfated
32 Proteoglycans in Astroglial Barriers Inhibit Neurite Outgrowth *in Vitro*. *Exp
33 Neurol* 1990;109;111-30.
- 34 34. Snow DM, Mullins N, Hynds DL. Nervous System-Derived Chondroitin
35 Sulfate Proteoglycans Regulate Growth Cone Morphology and Inhibit
36 Neurite Outgrowth: A Light, Epifluorescence, and Electron Microscopy
37 Study. *Microsc Res Tech* 2001;54;273-86.

- 1 35. Tanaka H, Matsui T, Agata A, Tomura M, Kubota I, McFarland BK, Lee A,
2 Phillips HS, Shelton DL. Molecular Cloning and Expression of a Novel
3 Adhesion Molecule, SC1. *Neuron* 1991;7;535-45.
- 4 36. Camu W, Henderson CE. Purification of embryonic rat motoneurons by
5 panning on a monoclonal antibody to the low-affinity NGF receptor. *J*
6 *Neurosci Methods* 1992;44;59-70.
- 7 37. Bartsch U, Bandtlow CE, Schnell L, Bartsch S, Spillmann AA, Rubin BP,
8 Hillenbrand R, Montang D, Schwab ME, Schachner M. Lack of Evidence
9 That Myelin-Associated Glycoprotein is a Major Inhibitor of Axonal
10 Regeneration in the CNS. *Neuron* 1995;15;1375-81.
- 11 38. Tang S, Woodhall RW, Shen YJ, deBellard ME, Saffell JL, Doherty P,
12 Walsh FS, Filbin MT. Soluble Myelin-Associated Glycoprotein (MAG)
13 Found *in Vivo* Inhibits Axonal Regeneration. *Mol Cell Neurosci*
14 1997;9;333-46.
- 15 39. Mehta NR, Lopez PHH, Vyas AA, Schnaar RL. Gangliosides and Nogo
16 Receptors Independently Mediate Myelin-associated Glycoprotein
17 Inhibition of Neurite Outgrowth in Different Nerve Cells. *J Biol Chem*
18 2007;282;27875-86.
- 19 40. Yip JW, Yip YP. Laminin—developmental expression and role in axonal
20 outgrowth in the peripheral nervous system of the chick. *Brain Res Dev*
21 *Brain Res* 1992;68;23-33.
- 22 41. Cramer KS, Karam SD, Bothwell M, Cerretti DP, Pasquale EB, Rubel EW.
23 Expression of EphB receptors and EphrinB ligands in the developing chick
24 auditory brainstem. *J Comp Neurol* 2002;452;51-64.
- 25 42. O'Neill P, Whalley K, Ferretti P. Nogo and Nogo-66 Receptor in Human
26 and Chick: Implications for Development and Regeneration. *Dev*
27 *Dynamics* 2004;231;109-21.
- 28 43. Mauti O, Sadhu R, Gemayel J, Gesemann M, Stoeckli EL. Expression
29 patterns of plexins and neuropilins are consistent with cooperative and
30 separate functions during neural development. *BMC Dev Biol* 2006;6;32,
31 doi:10.1186/1471-213X-6-32.
- 32 44. Cooper MA, Crockett DP, Nowakowski RS, Gale NW, Zhou R. Distribution
33 of EphA5 receptor protein in the developing and adult mouse nervous
34 system. *J Comp Neurol* 2009;514;310-28.
- 35 45. Spencer K, Mellado W, Filbin MT. BDNF Activates CaMKIV and PKA in
36 Parallel to Block MAG-mediated Inhibition of Neurite Outgrowth. *Mol Cell*
37 *Neurosci* 2008;38; 110-16.

- 1 46. Shen YJ, DeBellard ME, Salzer JL, Roder J, Filbin MT. Myelin-associated
2 in myelin and expressed by Schwann cells inhibits axonal regeneration
3 and branching. *Mol Cell Neurosci* 1998;12;79-91.
- 4 47. Douglas MR, Morrison KC, Leadbeater WE, Gonzalez AM, Berry M,
5 Logan A, Ahmed Z. Off-target effects of epidermal growth factor receptor
6 antagonists mediate retinal ganglion cell disinhibited axon growth. *Brain*
7 2009;132;3102-21.
- 8 48. Mizuno T, Yamashita T, Thyme M. Chimaeras act downstream from
9 neurotrophins in overcoming the inhibition of neurite outgrowth produced
10 by myelin-associated glycoprotein. *J Neurochem* 2004;91;395-403
- 11 49. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human
12 mesenchymal stem cell subpopulations express a variety of neuro-
13 regulatory molecules and promote neuronal cell survival and
14 neuritogenesis. *Exp Neurol* 2006;198;54-64.
- 15 50. Aizman I, Tate CC, McGrogan M, Case CC. Extracellular matrix produced
16 by bone marrow stromal cells and by their derivative, SB623 cells,
17 supports neural cell growth. *J Neurosci Res* 2009;87;3198-206.
- 18 51. Tondreau T, Meuleman N, Stamatopoulos B, De Bruyn C, Delforge A,
19 Dejeneffe M, Martiat P, Bron, D, Lagneaux L. *In vitro* study of matrix
20 metalloproteinase/tissue inhibitor metalloproteinase production by
21 mesenchymal stromal cells in response to inflammatory cytokines: the role
22 of their migration in injured tissues. *Cytotherapy* 2009;11;559-69.
- 23

1 **Figure Legends**

2 Figure 1. Nitrocellulose promotes optimal growth of embryonic chick spinal
3 neuronal cultures. A: Spinal cord cells formed many small fibroblastic aggregates
4 with few neurites on plastic alone, larger cell aggregates with some neurites were
5 formed on plastic pre-coated with laminin. Similar large cell aggregates were
6 formed on nitrocellulose alone but with many more associated neurites. Cells
7 seeded onto nitrocellulose pre-coated with laminin formed an almost confluent
8 fibroblastic culture with few neurites. Examples of neurites are indicated by black
9 arrows. Digitized images under phase contrast microscopy (calibration bar =
10 100 μ m). B: The number of cell aggregates with neurites was significantly
11 increased on nitrocellulose substrates alone compared to plastic (with or without
12 laminin) (* $p=0.0042$ and * $p=0.0062$ respectively, Mann Whitney U test: data
13 shown are from at least 5 separate cultures and 5 separate images per culture
14 combined \pm SEM). **No quantitation was attempted for nitrocellulose and laminin**
15 **substrates, which supported few distinguishable cell aggregates or neurites**
16 **amongst an almost confluent monolayer of fibroblastic cells.** C: Most cell
17 aggregates on plastic substrates were lost following fixation and immunostaining,
18 some neurofilament staining of neuronal bodies and neurites was observed on
19 plastic pre-coated with laminin. On nitrocellulose alone many neuronal bodies
20 were immunopositive for neurofilament as were a complex network of associated
21 neurites. The nuclei of cells seeded onto nitrocellulose pre-coated with laminin
22 were stained but few neurites were visible. Digitized images under fluorescence
23 microscopy (calibration bar = 100 μ m). D: After immunostaining for neurofilament

1 the number of neuronal bodies with neurites was significantly increased on
2 nitrocellulose substrates alone compared to plastic (with or without laminin)
3 (* $p=0.0034$ and * $p=0.0067$ respectively, Mann Whitney U test: data shown are
4 from at least 5 separate cultures and 5 separate images per culture combined \pm
5 SEM). Again, no quantitation was attempted for nitrocellulose and laminin
6 substrates as few distinguishable cell aggregates, neuronal bodies or neurites
7 were visible.

8 Figure 2. Embryonic chick spinal neuronal cultures are immunopositive for SC1,
9 a motor neuron marker. A-E: Representative digitized images of identical fields
10 are shown from left to right. Left panels show phase images and right panels
11 show immunolocalisation for SC1 (A and C) and isotype matched controls (B and
12 D). A and B are DRG explants (negative for SC1 staining), C and D are spinal
13 neuronal cultures (positive for SC1 staining). Calibration bars = 100 μm . E: At low
14 magnification, encompassing a wide field of view, many if not all neuronal bodies
15 and neurite networks in spinal neuronal cultures were immunopositive for SC1.
16 Calibration bar = 500 μm . F: At high magnification, uniform SC1 immunopositivity
17 was visible throughout the numerous cell bodies which cluster to form neuronal
18 bodies but also along the length of each neurite emanating from them.
19 Calibration bar = 100 μm .

20 Figure 3. Neurocan, Nogo-A and MAG spinal neuronal adhesion and neurite
21 outgrowth assays. A-C Digitized images of fluorescence microscopy show NF
22 immunolabelled neuronal bodies and neurites (dotted lines illustrate the location
23 of the neurocan, Nogo-A or MAG borders, calibration bars = 100 μm). A:

1 Neurocan substrates repelled neuronal adhesion and neurite outgrowth in a dose
2 dependant manner. The difference in the frequency of neuronal bodies with
3 neurites which had adhered to neurocan substrates compared to nitrocellulose
4 was significant at concentrations of 1, 5, 10 and 50 μ g/ml (** $p=0.059$ and
5 *** $p<0.0001$ Mann Whitney *U* test). B: Nogo-A substrates repelled neuronal
6 adhesion and neurite outgrowth in a dose dependant manner. The difference in
7 the frequency of neuronal bodies with neurites which had adhered to Nogo-A
8 substrates compared to nitrocellulose was significant at concentrations of 50,
9 100, 200 and 400 μ g/ml (*** $p<0.0001$ Mann Whitney *U* test). C: There was no
10 difference in the frequency of neuronal bodies with neurites which had adhered to
11 MAG substrates compared to nitrocellulose at any of the concentrations tested
12 (10, 50, 100, 200 or 400 μ g/ml). Data shown are from at least 5 separate cultures
13 and 5 separate images per culture combined +/-SEM.


14 Figure 4. In MSC co-cultures, the inhibitory effects of neurocan and Nogo-A
15 substrates on neuronal adhesion and neurite outgrowth were reduced. MSC co-
16 cultures also enhanced neuronal adhesion and neurite outgrowth over MAG. A-
17 C: Digitized images of identical fields are shown from left to right under
18 fluorescence microscopy (left panels illustrate the location of the neurocan,
19 Nogo-A or MAG and fluorescently labelled MSC, dotted lines illustrate the
20 location of substrate borders, right panels show NF immunolabelled neuronal
21 bodies and neurites, calibration bars = 100 μ m). A: MSC adhesion was reduced
22 on high concentrations of neurocan (10 and 50 μ g/ml) compared to nitrocellulose
23 (* $p=0.0217$ and *** $p<0.0001$ Mann Whitney *U* test). Neuronal adhesion and

1 neurite extension was only inhibited at the highest concentration of neurocan
2 (50 μ g/ml) in MSC co-cultures ($***p < 0.0001$ Mann Whitney *U* test). B: MSC
3 adhesion was reduced on 400 μ g/ml Nogo-A substrates compared to
4 nitrocellulose ($***p < 0.0001$ Mann Whitney *U* test). Neuronal adhesion and neurite
5 extension was only inhibited at the highest concentration of Nogo-A (400 μ g/ml) in
6 MSC co-cultures ($***p < 0.0001$ Mann Whitney *U* test). C: There was no difference
7 in the frequency of MSC or neuronal bodies with neurites which had adhered to
8 MAG substrates compared to nitrocellulose at any of the concentrations tested
9 (10, 50, 100, 200 or 400 μ g/ml). Black arrows indicate co-localisation of MSC and
10 spinal neurites, white arrows indicate independent binding of neurites to inhibitory
11 substrates. Data shown are from at least 5 separate cultures and 5 separate
12 images per culture combined +/-SEM. D: Merged digitized phase and
13 fluorescence images are shown (illustrating the location of MSC associated
14 laminin or fibronectin, dotted lines illustrate the location of substrate borders,
15 calibration bars = 100 μ m). MSC shown bridging nerve inhibitory substrata were
16 immunopositive for laminin (right panel) and fibronectin.(middle panel). Left panel
17 illustrates negative control staining for polyclonal antibodies.


18 Figure 5. MSC conditioned media (MSC-CM) stimulates spinal neurite outgrowth,
19 but not over inhibitory neurocan or Nogo-A substrata. A: Representative digitized
20 images of neurite outgrowth over nitrocellulose in control media (top panel) and
21 MSC-CM (bottom panel) under phase contrast microscopy are shown with
22 digitized CellIQ® 'neurite finder' overlays, calibration bars = 100 μ m. Analysing
23 pooled data (n=6 MSC-CM) demonstrated a marked and significant increase in

1 neurite length following culture in MSC-CM compared to control medium
2 (* $p < 0.0384$ Mann Whitney *U* test). B: MSC-CM contained several neurotrophic
3 proteins which were detected using custom designed antibody arrays. Arbitrary
4 signal intensity readings were normalised to MSC number, data shown are from
5 MSC-CM combined +/-SEM. C: MSC-CM was not sufficient stimuli to promote
6 neurite extension over inhibitory substrata of neurocan (top panel) or Nogo-A
7 (bottom panel). Digitized images are shown under fluorescence microscopy show
8 NF immunolabelled neuronal bodies and neurites (dotted lines illustrate the
9 location of the neurocan or Nogo-A, calibration bars = 100 μ m). There was no
10 difference in the frequency of neuronal bodies with neurites which had adhered to
11 nitrocellulose or inhibitory neurocan or Nogo-A substrata in neuronal growth
12 media compared MSC-CM. Data shown are from at least 5 separate cultures and
13 5 separate images per culture combined +/-SEM.

Figure 1



B



D




Figure 2














Figure 3









Figure 4








Figure 5

A



B



C







Figure 1 tiff

[Click here to download high resolution image](#)






Figure 2 tiff
[Click here to download high resolution image](#)




Figure 3 tiff
[Click here to download high resolution image](#)









Figure 4 tiff
[Click here to download high resolution image](#)








Figure 5 tiff
[Click here to download high resolution image](#)



***Disclosure - TSJ-ICMJE Form**

[Click here to download Disclosure - TSJ-ICMJE Form: JB Disclosure.pdf](#)

***Disclosure - TSJ-ICMJE Form**

[Click here to download Disclosure - TSJ-ICMJE Form: KU Disclosure.pdf](#)

***Disclosure - TSJ-ICMJE Form**

[Click here to download Disclosure - TSJ-ICMJE Form: KW Disclosure.pdf](#)

***Disclosure - TSJ-ICMJE Form**

[Click here to download Disclosure - TSJ-ICMJE Form: SR Disclosure.pdf](#)

***Disclosure - TSJ-ICMJE Form**

[Click here to download Disclosure - TSJ-ICMJE Form: WE Disclosure.pdf](#)

***Disclosure - TSJ-ICMJE Form**

[Click here to download Disclosure - TSJ-ICMJE Form: WJ Disclosure.pdf](#)

***Affirmation of Authorship Form**

[Click here to download Affirmation of Authorship Form: Affirmation Authorship.pdf](#)

***FDA Drug/Device Approval Form**

[Click here to download FDA Drug/Device Approval Form: FDA approval.pdf](#)